Active Biotech in Brief

Active Biotech develops pharmaceutical products within medical areas where the immune system is of significant importance, including cancer and inflammatory eye diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Active Biotech has its base in Lund, Sweden and was formed in 1998 as a spin-off from Pharmacia & Upjohn. The share is listed and traded on Nasdaq Stockholm (Small Cap). The Company has core competence in cancer and inflammatory diseases and a competent team with extensive experience in drug development from early to late stage clinical development.

Beginning of 2020, new direction for the company was announced and the project portfolio is now composed of:

  • Tasquinimod is in clinical development for hematological cancers. A phase Ib/IIa study of tasquinimod in multiple myeloma is ongoing. Planning is underway for the start of a clinical study in myelofibrosis.
  • Laquinimod is in clinical development for inflammatory eye disorders. A phase I clinical study with a proprietary developed eye drop formulation of laquinimod has been completed. Preparations are underway for a clinical biodistribution study of the eye drop formulation
  • Naptumomab estafenatox (Naptumomab), licensed to NeoTX Therapeutics Ltd., is in clinical development for treatment of solid tumors. A phase II a study in non-small cell lung cancer (NSCLC) and a phase Ib/II study in selected solid tumors are ongoing
Where the immune defense is of significant importance